Cargando…

Identification of novel lactate metabolism signatures and molecular subtypes for prognosis in hepatocellular carcinoma

Background: Evidence has shown that lactate, an immune signaling molecule, is associated with hepatocellular carcinoma (HCC) progression and immune suppression. Therefore, identifying lactate metabolism-related molecules is a promising therapeutic strategy to inhibit the development of HCC and overc...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Qiutong, Pan, Jing, Ren, Ninghui, Qiao, Chu, Wei, Minjie, Li, Zhenhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486814/
https://www.ncbi.nlm.nih.gov/pubmed/36147735
http://dx.doi.org/10.3389/fcell.2022.960277
_version_ 1784792362018406400
author Guan, Qiutong
Pan, Jing
Ren, Ninghui
Qiao, Chu
Wei, Minjie
Li, Zhenhua
author_facet Guan, Qiutong
Pan, Jing
Ren, Ninghui
Qiao, Chu
Wei, Minjie
Li, Zhenhua
author_sort Guan, Qiutong
collection PubMed
description Background: Evidence has shown that lactate, an immune signaling molecule, is associated with hepatocellular carcinoma (HCC) progression and immune suppression. Therefore, identifying lactate metabolism-related molecules is a promising therapeutic strategy to inhibit the development of HCC and overcome chemotherapy resistance. Long noncoding RNAs (lncRNAs) are related to tumorigenesis and metastasis. Hence, verifying the molecular subtypes of lncRNAs related to lactate metabolism will play a critical role in managing HCC. Methods: Based on HCC data in The Cancer Genome Atlas (TCGA), lactate metabolic pathway-related genes were enriched by gene collection and enrichment analysis (GSEA). Lactate metabolism-related lncRNAs (LM_lncRNAs) were identified by correlation analysis, HCC molecular subtypes were determined using nonnegative matrix factorization (NMF) clustering, and the response of the three subtypes to chemotherapeutics was further evaluated using the Genomic Tumor Sensitive Cell Line (GDSC) dataset. LM_lncRNAs were examined via Lasso-Cox regression analysis to determine prognosis for patients. A Nomagram plot was used to predict patient survival time. Results: Three molecular subtypes of HCC were identified. The survival rate of patients with C1 subtype was higher than that of those with C2 and C3. Additionally, patients with C3 subtype have higher levels of immune cell infiltration and high expression of genes related to immune checkpoints. The GDSC results indicated that patients with C3 subtypes were more sensitive to chemotherapy drugs such as sorafenib and sunitinib. The prognostic risk assessment model consisted of six risk factors (AC034229.4, AC131009.1, MYOSLID, AC008667.1, AC012073.1, AC068025.1) and two protective factors (LINC00402 and AC103858.1). Based on Kaplan-Meier analysis, low-risk HCC patients had a high survival rate, and the receiver operating characteristic curve (ROC), calibration curve, and C-index confirmed good prediction ability. Conclusion: In this study, the molecular subtyping method and prediction model of lactate metabolism-related lncRNAs (LM_lncRNAs) were constructed for the prognosis of HCC patients. This work demonstrated the potential targets of LM_lncRNAs and provided a novel perspective and therapeutic paradigm for future clinical translation.
format Online
Article
Text
id pubmed-9486814
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94868142022-09-21 Identification of novel lactate metabolism signatures and molecular subtypes for prognosis in hepatocellular carcinoma Guan, Qiutong Pan, Jing Ren, Ninghui Qiao, Chu Wei, Minjie Li, Zhenhua Front Cell Dev Biol Cell and Developmental Biology Background: Evidence has shown that lactate, an immune signaling molecule, is associated with hepatocellular carcinoma (HCC) progression and immune suppression. Therefore, identifying lactate metabolism-related molecules is a promising therapeutic strategy to inhibit the development of HCC and overcome chemotherapy resistance. Long noncoding RNAs (lncRNAs) are related to tumorigenesis and metastasis. Hence, verifying the molecular subtypes of lncRNAs related to lactate metabolism will play a critical role in managing HCC. Methods: Based on HCC data in The Cancer Genome Atlas (TCGA), lactate metabolic pathway-related genes were enriched by gene collection and enrichment analysis (GSEA). Lactate metabolism-related lncRNAs (LM_lncRNAs) were identified by correlation analysis, HCC molecular subtypes were determined using nonnegative matrix factorization (NMF) clustering, and the response of the three subtypes to chemotherapeutics was further evaluated using the Genomic Tumor Sensitive Cell Line (GDSC) dataset. LM_lncRNAs were examined via Lasso-Cox regression analysis to determine prognosis for patients. A Nomagram plot was used to predict patient survival time. Results: Three molecular subtypes of HCC were identified. The survival rate of patients with C1 subtype was higher than that of those with C2 and C3. Additionally, patients with C3 subtype have higher levels of immune cell infiltration and high expression of genes related to immune checkpoints. The GDSC results indicated that patients with C3 subtypes were more sensitive to chemotherapy drugs such as sorafenib and sunitinib. The prognostic risk assessment model consisted of six risk factors (AC034229.4, AC131009.1, MYOSLID, AC008667.1, AC012073.1, AC068025.1) and two protective factors (LINC00402 and AC103858.1). Based on Kaplan-Meier analysis, low-risk HCC patients had a high survival rate, and the receiver operating characteristic curve (ROC), calibration curve, and C-index confirmed good prediction ability. Conclusion: In this study, the molecular subtyping method and prediction model of lactate metabolism-related lncRNAs (LM_lncRNAs) were constructed for the prognosis of HCC patients. This work demonstrated the potential targets of LM_lncRNAs and provided a novel perspective and therapeutic paradigm for future clinical translation. Frontiers Media S.A. 2022-09-02 /pmc/articles/PMC9486814/ /pubmed/36147735 http://dx.doi.org/10.3389/fcell.2022.960277 Text en Copyright © 2022 Guan, Pan, Ren, Qiao, Wei and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Guan, Qiutong
Pan, Jing
Ren, Ninghui
Qiao, Chu
Wei, Minjie
Li, Zhenhua
Identification of novel lactate metabolism signatures and molecular subtypes for prognosis in hepatocellular carcinoma
title Identification of novel lactate metabolism signatures and molecular subtypes for prognosis in hepatocellular carcinoma
title_full Identification of novel lactate metabolism signatures and molecular subtypes for prognosis in hepatocellular carcinoma
title_fullStr Identification of novel lactate metabolism signatures and molecular subtypes for prognosis in hepatocellular carcinoma
title_full_unstemmed Identification of novel lactate metabolism signatures and molecular subtypes for prognosis in hepatocellular carcinoma
title_short Identification of novel lactate metabolism signatures and molecular subtypes for prognosis in hepatocellular carcinoma
title_sort identification of novel lactate metabolism signatures and molecular subtypes for prognosis in hepatocellular carcinoma
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486814/
https://www.ncbi.nlm.nih.gov/pubmed/36147735
http://dx.doi.org/10.3389/fcell.2022.960277
work_keys_str_mv AT guanqiutong identificationofnovellactatemetabolismsignaturesandmolecularsubtypesforprognosisinhepatocellularcarcinoma
AT panjing identificationofnovellactatemetabolismsignaturesandmolecularsubtypesforprognosisinhepatocellularcarcinoma
AT renninghui identificationofnovellactatemetabolismsignaturesandmolecularsubtypesforprognosisinhepatocellularcarcinoma
AT qiaochu identificationofnovellactatemetabolismsignaturesandmolecularsubtypesforprognosisinhepatocellularcarcinoma
AT weiminjie identificationofnovellactatemetabolismsignaturesandmolecularsubtypesforprognosisinhepatocellularcarcinoma
AT lizhenhua identificationofnovellactatemetabolismsignaturesandmolecularsubtypesforprognosisinhepatocellularcarcinoma